
### [NCIT:C3867](http://purl.obolibrary.org/obo/NCIT_C3867)
**Label:** Fallopian Tube Carcinoma

**Subclasses:** [NCIT:C115429](http://purl.obolibrary.org/obo/NCIT_C115429) (Recurrent Fallopian Tube Carcinoma), [NCIT:C6265](http://purl.obolibrary.org/obo/NCIT_C6265) (Fallopian Tube Adenocarcinoma), [NCIT:C6279](http://purl.obolibrary.org/obo/NCIT_C6279) (Fallopian Tube Endometrioid Adenocarcinoma), [NCIT:C6278](http://purl.obolibrary.org/obo/NCIT_C6278) (Fallopian Tube Gestational Choriocarcinoma), [NCIT:C6267](http://purl.obolibrary.org/obo/NCIT_C6267) (Fallopian Tube Papillary Adenocarcinoma), [NCIT:C40104](http://purl.obolibrary.org/obo/NCIT_C40104) (Fallopian Tube Transitional Cell Carcinoma), [NCIT:C40105](http://purl.obolibrary.org/obo/NCIT_C40105) (Stage 0 Fallopian Tube Cancer), [NCIT:C6280](http://purl.obolibrary.org/obo/NCIT_C6280) (Fallopian Tube Clear Cell Adenocarcinoma), [NCIT:C126449](http://purl.obolibrary.org/obo/NCIT_C126449) (Serous Tubal Intraepithelial Carcinoma), [NCIT:C40455](http://purl.obolibrary.org/obo/NCIT_C40455) (Hereditary Fallopian Tube Carcinoma), [NCIT:C40103](http://purl.obolibrary.org/obo/NCIT_C40103) (Fallopian Tube Mucinous Adenocarcinoma), [NCIT:C6282](http://purl.obolibrary.org/obo/NCIT_C6282) (Fallopian Tube Squamous Cell Carcinoma), [NCIT:C6281](http://purl.obolibrary.org/obo/NCIT_C6281) (Undifferentiated Fallopian Tube Carcinoma), [NCIT:C126456](http://purl.obolibrary.org/obo/NCIT_C126456) (High Grade Fallopian Tube Serous Adenocarcinoma), [NCIT:C40099](http://purl.obolibrary.org/obo/NCIT_C40099) (Fallopian Tube Serous Adenocarcinoma), [NCIT:C126457](http://purl.obolibrary.org/obo/NCIT_C126457) (Low Grade Fallopian Tube Serous Adenocarcinoma), 

**Class expressions from DL-Learner:**

- Thing 53.94%
- [UBERON:0003889](http://purl.obolibrary.org/obo/UBERON_0003889) (fallopian tube) 53.33%
- [UBERON:0000474](http://purl.obolibrary.org/obo/UBERON_0000474) (female reproductive system) 53.33%
- [NCIT:C41361](http://purl.obolibrary.org/obo/NCIT_C41361) (KRAS Gene Mutation) 53.33%
- [NCIT:C40430](http://purl.obolibrary.org/obo/NCIT_C40430) (BRAF Gene Mutation) 53.33%
- [NCIT:C36689](http://purl.obolibrary.org/obo/NCIT_C36689) (BRCA2 Gene Inactivation) 53.33%
- [NCIT:C36688](http://purl.obolibrary.org/obo/NCIT_C36688) (BRCA1 Gene Inactivation) 53.33%
- [NCIT:C25785](http://purl.obolibrary.org/obo/NCIT_C25785) (KRAS Gene) 53.33%
- [NCIT:C19636](http://purl.obolibrary.org/obo/NCIT_C19636) (BRCA2 Gene Mutation) 53.33%
- [NCIT:C19635](http://purl.obolibrary.org/obo/NCIT_C19635) (BRCA1 Gene Mutation) 53.33%
- [NCIT:C18363](http://purl.obolibrary.org/obo/NCIT_C18363) (BRAF Gene) 53.33%
- [NCIT:C18120](http://purl.obolibrary.org/obo/NCIT_C18120) (BRCA2 Gene) 53.33%
- [NCIT:C17965](http://purl.obolibrary.org/obo/NCIT_C17965) (BRCA1 Gene) 53.33%
- [NCIT:C17359](http://purl.obolibrary.org/obo/NCIT_C17359) (TP53 Gene) 53.33%
- [NCIT:C118396](http://purl.obolibrary.org/obo/NCIT_C118396) (TP53 Gene Mutation) 53.33%


